- Price
- $3.31
- Day
- +4.09%
- Mkt Cap
- $1.74B
- 52W Range
- $2.77 – $7.18
- Volume
- 21.40M
- Beta
- 1.05
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated targets for drug discovery REC-4881 (MEK1/2 inhibitor): Additional Phase 2 data in Familial Adenomatous Polyposis (FAP) to be presented at the Presidential Plenary session at leading hereditary GI annual meeting in November 2026 REC-7735 (PI3Kα H1047R inhibitor): IND cleared, Phase 1/2 trial start in 2H26; a >100× mutant-selective PI3Kα H1047R inhibitor designed to improve therapeutic index by enabling deep suppression of the most common activating PI3Kα mutation while sparing wild-type PI3Kα Reduced 2026 cash operating expense guidance to 100-fold selectivity for the H1047R mutant over wild type in order to drive high, sustained target inhibition while avoiding hyperinsulinemia-driven reactivation The differentiated development candidate was delivered in 10 months and 242 compounds from first novel hit through Recursion's AI-native design platform, demonstrating the Company's ability to rapidly translate platform insights into optimized clinical candidates With the IND cleared, the Phase 1/2 ZINNIA clinical study for patients with select PIK3CA H1047R-mutant solid tumors will be initiated in the second half of 2026 For the rest of the portfolio, programs continue to progress as planned. Additional expected upcoming milestones across Recursion's internal pipeline: REC-1245 (RBM39): Additional Phase 1 dose escalation data expected in 2H26 REC-617 (CDK7): Early Phase 1 safety and PK combination data expected in 1H27 REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27 REC-4539 (LSD1): Early Phase 1 safety and PK monotherapy data expected in 2H27 Agentic AI is compounding Recursion's advantage across Biology, Design, and ClinTech: Target Discovery Agent pairs frontier AI reasoning with Recursion's proprietary multimodal maps to surface novel drug targets, enabling scientists to mine and extract insights from proprietary maps in hours rather than weeks.
Read full article
Salt Lake City, UT, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following upcoming investor conferences: Bank of America 2026 SMID Cap Executive Insights Event — Tuesday, August 11, 2026 Morgan Stanley 24th Annual Global Healthcare Conference — Tuesday, September 15, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com . About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company decoding biology to radically improve lives.
Read full article
Salt Lake City, UT, July 31, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on July 27, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 3,234,866 shares of its class A common stock in the aggregate to 24 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award was granted as an inducement material to the employee's commencement of employment with Recursion, or a subsidiary of Recursion, pursuant to Nasdaq Listing Rule 5635(c)(4).
Read full article
Analysts remain optimistic that the market will view upcoming catalysts in a bullish light.
Read full article
Salt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) -- Salt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) – Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its second quarter 2026 financial results on Wednesday, August 5, 2026, before the open of the financial markets. Recursion will host an earnings call on Aug 5, 2026 at 8:00 AM ET / 6:00 AM MT / 1:00 PM BST.
Read full article
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $2.97, representing a -2.62% change from its previous close.
Read full article
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $3.01, denoting a +1.69% move from the preceding trading day.
Read full article
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
Read full article
Amova Asset Management Americas Inc. decreased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) by 12.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,419,221 shares of the company's stock after selling 801,804 shares during the period. Amova Asset
Read full article
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $2.89, denoting a -1.87% move from the preceding trading day.
Read full article
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.34, indicating a +1.21% shift from the previous trading day.
Read full article